Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile
1 other identifier
observational
120
1 country
1
Brief Summary
the goal of the randomized controlled observational study is to observe the effect of subclinical hypothyroidism on liver enzymes and lipid profile
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 15, 2025
CompletedFirst Posted
Study publicly available on registry
November 19, 2025
CompletedStudy Start
First participant enrolled
December 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
November 19, 2025
September 1, 2025
1 year
November 15, 2025
November 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile
1. Mean levels of liver enzymes (ALT, AST, GGT) • To determine whether there is a statistically significant difference in liver enzyme levels between individuals with subclinical hypothyroidism and euthyroid controls. 2. Mean values of lipid profile components (Total Cholesterol, LDL-C, HDL-C, Triglycerides) • To assess whether subclinical hypothyroidism is associated with dyslipidemia compared to the control group.
Baseline
Interventions
subclinical hypothyroidism on liver enzymes and lipid profile
Eligibility Criteria
internal medicine department
You may qualify if:
- Age ≥ 18 years
- For SCH group: Elevated TSH with normal FT4
- For control group: Normal TSH and FT4 levels
You may not qualify if:
- Evident hypothyroidism or hyperthyroidism
- Diagnosed with diabetes mellitus
- Chronic liver disease
- Chronic kidney disease
- Use of lipid-lowering or thyroid medications
- Pregnancy
- Alcohol abuse
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut university hospitals
Asyut, Egypt
Related Publications (2)
Shan Z, Chen L, Lian X, Liu C, Shi B, Shi L, Tong N, Wang S, Weng J, Zhao J, Teng X, Yu X, Lai Y, Wang W, Li C, Mao J, Li Y, Fan C, Teng W. Iodine Status and Prevalence of Thyroid Disorders After Introduction of Mandatory Universal Salt Iodization for 16 Years in China: A Cross-Sectional Study in 10 Cities. Thyroid. 2016 Aug;26(8):1125-30. doi: 10.1089/thy.2015.0613. Epub 2016 Jul 22.
PMID: 27370068RESULTMavromati M, Jornayvaz FR. Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD. Int J Mol Sci. 2021 Nov 26;22(23):12797. doi: 10.3390/ijms222312797.
PMID: 34884625RESULT
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Muhammad Abbas Said, professor
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- resident
Study Record Dates
First Submitted
November 15, 2025
First Posted
November 19, 2025
Study Start
December 1, 2025
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
November 19, 2025
Record last verified: 2025-09